Cover caption

Abstract

As medical advances enable the detection of smaller and smaller cancers, it becomes very important to determine which lesions will progress to an aggressive malignancy. For example, mammography has increased the detection of ductal carcinoma in situ (DCIS), however, after surgery, about 15% of these women will progress to invasive breast cancer. Determining how to identify these women whose disease will progress has been problematic. In the current issue of Cancer Biology & Therapy, Michael Lisanti’s group demonstrates that patients will low or no stromal caveolin-1 are more likely to progress to invasive breast cancer. This month’s cover image shows a section from a patient's breast showing strong caveolin-1 expression (brown) in her stromal fibroblasts. Cells are counterstained with hematoxylin. To learn more about caveolin-1 as a marker for DCIS progression to invasive cancer, see the article by Witkiewicz et al.